Clinical Trial: Eplerenone for the Treatment of Central Serous Chorioretinopathy

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Eplerenone for the Treatment of Central Serous Chorioretinopathy

Brief Summary: To test the effect oral eplerenone versus placebo in patients with central serious chorioretinopathy .

Detailed Summary: To evaluate the effect of oral eplerenone compared to placebo in patients with central serous chorioretinopathy (CSCR) on sub-foveal (small part of retina) fluid using optical coherence tomography (OCT).
Sponsor: Wills Eye

Current Primary Outcome: Absence of sub-foveal (retinal) fluid based on spectral domain optical coherence tomography (OCT) measurement. [ Time Frame: At 1 month in acute CSCR and 2 months in chronic CSR patients ]

Placebo versus eplerenone acute CSCR patients will have sub-foveal fluid measured at month 1, and placebo versus eplerenone chronic cscr patients will be have sub-foveal fluid measured at month 2.


Original Primary Outcome: Same as current

Current Secondary Outcome: Mean change in subfoveal fluid height based on OCT measurement [ Time Frame: Month 1 for acute CSCR patients, Month 2 in chronic CSCR patients ]

Placebo versus eplerenone acute CSCR patients will be measured at month 1 and placebo versus eplerenone chronic CSCR patients will be measured at month 2.


Original Secondary Outcome: Same as current

Information By: Wills Eye

Dates:
Date Received: November 15, 2013
Date Started: October 2013
Date Completion:
Last Updated: January 9, 2017
Last Verified: January 2017